Q2 2025 Quest Diagnostics Inc Earnings Call Transcript
Key Points
- Quest Diagnostics Inc (DGX) reported strong top line growth of 15.2% in the second quarter, including 5.2% organic revenue growth.
- The company raised its full year 2025 guidance due to strong performance and continued utilization trends.
- Quest Diagnostics Inc (DGX) achieved an 11.5% increase in adjusted earnings per share, driven by top line growth and productivity gains from automation and digitization.
- The company saw approximately 20% revenue growth in the physician channel, primarily driven by acquisitions and complemented by organic growth.
- Quest Diagnostics Inc (DGX) is expanding its consumer channel, with strong growth in offerings such as a new women's hormone panel on questhealth.com.
- Total revenue per requisition decreased by 0.4% compared to the prior year, primarily due to the impact of the LifeLabs acquisition.
- Higher interest expenses impacted the reported EPS in the second quarter.
- The company faces potential challenges from the One Big Beautiful Bill, which could lead to 10 million more uninsured individuals over the next few years.
- Quest Diagnostics Inc (DGX) anticipates approximately 30 basis points of impact on volumes in 2026 due to changes in exchange subsidies.
- The company is absorbing the impact of tariffs from China and Europe, which could affect financial performance.
Welcome to the Quest Diagnostics second quarter 2025 conference call. At the request of the company, this call is being recorded. The entire contents of this call, including the presentation and question-and-answer session that will follow for the property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.
Now I would like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Please go ahead.
Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer, and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
